Table 1.
Clinical characteristics of 391 patients in this analysis
| Characteristics at diagnosis | Value (%) |
|---|---|
| Age (years, mean and SD) | 59 ± 15 |
| Male | 221 (57) |
| Origin of AML | |
| de novo AML | 302 (77) |
| s-AML | 68 (17) |
| t-AML | 24 (6) |
| 2017 ELN risk | |
| Favorable | 99 (25) |
| Favorable or intermediate | 10 (3) |
| Intermediate | 78 (20) |
| Intermediate or adverse | 6 (2) |
| Adverse | 122 (31) |
| No information | 76 (19) |
| Cytogenetic aberrations | |
| Favorable | 33 (8) |
| Intermediate | 205 (52) |
| Normal karyotype | 142 (36) |
| Adverse | 84 (21) |
| Complex karyotype | 64 (16) |
| No information | 70 (18) |
Abbreviations: ELN, European LeukemiaNet; AML, acute myelogenous leukemia.
Percentages may not total 100 due to rounding.
Three patients are in both the s-AML and t-AML subgroups.
AML, acute myeloid leukemia; ELN, European LeukemiaNet; s-AML, secondary acute myeloid leukemia; t-AML, therapy-related acute myeloid leukemia.